Abstract 1683P
Background
Myeloproliferative neoplasms (MPN) are chronic haematological malignancies including myelofibrosis (MF), polycythaemia vera (PV) and essential thrombocythemia (ET). People with MPN require proper education to confidently manage their health at home. If they develop high levels of self-care confidence, they might be more capable of performing self-care behaviours and improving their quality of life. This study aims to preliminary assess the self-care confidence of MPN patients and its association with their quality of life.
Methods
This is a descriptive cross-sectional study conducted by the Italian Association of MPN Patients (AIPAMM). Preliminary data from 9 haematology centres in Italy were analysed. During their outpatient visit, patients with MPN were given a paper-and-pencil questionnaire to measure self-care confidence using the Self-Care Confidence Scale, symptom burden using the MPN-SAF TSS, and quality of life using the EORTC QLQ-C30.
Results
The study included 292 adult patients with MPN (55% male; mean age = 60 years ± 14). They were diagnosed with MF (42%), ET (30%), or PV (28%). The most burdensome symptoms were fatigue, problems with concentration, abdominal discomfort, and inactivity. Participants rated their overall quality of life as 69.5 ± 22.8 (range 0-100). The mean level of self-care confidence was 77.4 ± 16.3 (range 0-100). We found that a higher level of self-care confidence is associated with lower symptom burden (r = -.24; p <. 001) and greater quality of life (r =. 30; p <. 001).
Conclusions
This study revealed that enhancing self-care confidence in MPN patients can decrease their symptom burden and improve their quality of life. Health professionals should educate and support people living with MPN in performing self-care behaviours to enhance their ability to manage their health at home and their level of confidence. In particular, patients should be empowered to utilize suitable strategies to address fatigue and problems with concentration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11